The National Institutes of Health (NIH) announced this week that not only has funding for the Consortium of Food Allergy Research (CoFAR) program been extended for an additional five years, but CoFAR’s scope has also been expanded to include research on eosinophilic gastrointestinal diseases (EGID), which are frequently comorbid with food allergies.
Like food allergies, EGIDs are IgE-mediated. The most common EGID presentation is eosinophilic esophagitis. The EGID studies will be led by Dr. Marc Rothenberg (Cincinnati Children’s Hospital), the co-editor of this section, and include researchers from the University of Colorado, Denver, and Children’s Hospital, Philadelphia.
An additional clinical trial for treatment of peanut allergy has been added to the research program. The new treatment delivers peanut protein transdermally. Further program expansion includes two sites to examine food allergy genetics.
Tell us what you think. Please feel free to post your own comments and/or predictions below. Topics and articles that you think would be of interest in our NBOP section and/or this blog can be sent to the JACI Editorial Office at jaci@njhealth.org.
No comments:
Post a Comment